Immunological Dynamics Associated with Direct-Acting Antiviral Therapies in Naive and Experimented HCV Chronic-Infected Patients

Table 1

Demographic and clinical characteristics of the control group and HCV patients before treatment.

	Control group ()	HCV patients ()	value
Demographics & clinical characteristics
Age ()			<0.0001^#
Gender (male/female)	36/14	18/17	—
HCV genotypes (1/2/3/4/1+2)	—	25/2/6/1/1	—
Naïve/experienced	—	27/8	—
≤F2 ()	—	18/17	—
>F2 ()	—	17/18	—
Child-Pugh A/B/C	—	31/2/2	—
Hypertension portal (yes/no)	—	8/27	—
DAA treatment
SOF+SMV	—	5	—
SOF+DCV	—	23	—
SOF+RBV	—	2	—
12/24 weeks	—	22/13	—
SVR/no SVR	—	34/1	—

^#Mann–Whitney test; SD: standard deviation; genotype: patient denied viral load prior to treatment. Patients present two HCV genotypes: naïve: patients without previous treatment, and experienced: patients with more than one therapy. FIB-4: noninvasive score to determine hepatic fibrosis; features . Portal hypertension: criteria for evaluation of portal hypertension: esophageal varices, thrombocytopenia, and splenomegaly; SOF/SMV: Sofosbuvir+Simeprevir; SOF/DCV: Sofosbuvir+Daclatasvir; SOF/RBV: Sofosbuvir+Ribavirin; SVR: sustained virological response; no SVR: no sustained virological response.